Log In
BCIQ
Print this Print this
 

CVXL-0069

  Manage Alerts
Collapse Summary General Information
Company Domain Therapeutics S.A.
DescriptionDual Adenosine A2A (ADORA2A) and Adenoside A1 (ADORA1) antagonist
Molecular Target Adenosine A2A receptor (ADORA2A) ; Adenosine A1 receptor (ADORA1)
Mechanism of ActionAdenosine A1 receptor antagonist; Adenosine A2A receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerCleveXel Pharma S.A.S.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today